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Abstract 
Background: Given the recent findings from pooled studies about a potential inverse association 
between selenium levels and prostate cancer risk, the current cross-sectional study aimed to 
investigate the association between serum selenium and serum concentrations of sex steroid 
hormones including estradiol in a nationally representative sample of US men to investigate one 
mechanism by which selenium may influence prostate cancer risk.  
Methods: The study included 1,420 men aged 20 years or older who participated in the Third 
National Health and Nutrition Examination Survey (NHANES III) between 1988 and 1994. We 
calculated age/race-ethnicity-adjusted and multivariable-adjusted geometric mean serum 
concentrations of total and estimated free testosterone and estradiol, androstanediol glucuronide 
(AAG), and sex hormone binding globulin (SHBG) and compared them across quartiles of serum 
selenium.  
Results: Adjusting for age, race/ethnicity, smoking status, serum cotinine, household income, 
physical activity, alcohol consumption and percent body fat, mean total estradiol (e.g. Q1: 38.00 
pg/mL (95%CI: 36.03-40.08) vs Q4: 35.29 pg/mL (33.53-37.14); Ptrend=0.050)and free estradiol [e.g. 
Q1: 0.96 pg/mL (95%CI: 0.92-1.01) vs Q4: 0.90 (95%CI: 0.85-0.95); Ptrend=0.065] concentrations 
decreased over quartiles of selenium. Stratification by smoking and alcohol consumption, showed 
that the latter observation was stronger for never smokers (Pinteraction=0.073) and those with limited 
alcohol intake (Pinteraction=0.017). No associations were observed for the other sex steroid hormones 
studied.  
Conclusion: Our findings suggests that a possible mechanism by which selenium may be protective 
for prostate cancer is related to estrogen.  
Impact: Further studies of longitudinal measurements of serum and toenail selenium in relation to 
serum measurements of sex steroid hormones are needed.  
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Introduction 
A recent Cochrane review indicated that findings for the potential anti-tumourigenic effects of 
selenium are inconsistent (1). In the context of prostate cancer, they identified 17 epidemiological 
studies, for which the summary OR was 0.79 (95%CI: 0.69-0.90) when comparing higher selenium 
exposure to lower. When stratifying by method of selenium assessment, an inverse association with 
prostate cancer risk was observed for higher baseline biomarkers (OR: 0.76; 95%CI: 0.67-0.88), but 
not for higher estimated dietary selenium intake (OR: 1.00; 95%CI: 0.73-1.36). Among the selenium 
biomarkers, the inverse association was stronger for toenail (OR: 0.53; 95%CI: 0.35-0.81) than blood 
(OR: 0.82; 95%CI: 0.72-0.93) levels (1). Recent findings of the Endogenous Hormones, Nutritional 
Biomarkers and Prostate Cancer Collaborative Group, which pooled primary data from prospective 
studies, corroborated this observation, noting that toenail selenium was inversely associated with 
total prostate cancer (OR: 0.29; 95%CI: 0.22-0.40), but not blood selenium (2).  
 
Some randomized controlled trials (RCT) have also observed beneficial effects of selenium 
supplements on prostate cancer risk as a secondary outcome (3, 4). In an RCT of 974 men with a 
history of either basal call or squamous cell carcinoma who were randomized to either a daily 
supplement of 200 µg of selenium or placebo, Clarke et al. showed that selenium was associated 
with 63% reduction in prostate cancer risk (p=0.002), but not the primary outcome of recurrent skin 
cancer (4). A secondary analysis of this RCT observed that significant reductions in prostate cancer 
risk were only observed for those with selenium concentrations <123.3 ng/mL (lowest two tertiles) 
(5). In contrast, the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a large RCT designed 
specifically to investigate selenium supplementation in the prevention of prostate cancer, did not 
show a benefit (6), including in men with lower baseline toenail selenium status (7).  
 
The biological mechanisms underlying a potential protective effect of selenium for cancer are not 
well understood. One mechanism suggested to explain a link between selenium and prostate cancer, 
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is genetic variation in selenoproteins and related antioxidant enzymes (8). Another more recently 
suggested hypothesis is focused on a link with sex steroid hormones. For example, even though 
estrogen therapy was historically used to decrease androgen levels of men with advanced prostate 
cancer, recent studies suggest a role in prostate carcinogenesis.  Estrogen has been shown to induce 
neoplastic epithelial morphology in both human and rat prostates and to regulate prostate specific 
gene expression. Anti-estrogens have also been shown to inhibit development and progression of 
prostate cancer under experimental and clinical conditions (9). 
 
 
Given the growing evidence for a role of estrogen in prostate cancer carcinogenesis (10), it is of 
interest to also investigate selenium action in relation to prostate cancer risk. For example, it is 
hypothesized that the progressive emergence of the ERalpha during prostate cancer progression and 
hormone refractory disease presents a mechanism through which the tumour can bypass androgens 
using estrogen and progesterone. Nevertheless, few studies have investigated the link between 
selenium and other sex steroid hormones such as testosterone and sex hormone-binding globulin 
(SHBG); no clear associations have been observed to date (11, 12).  
 
If underlying biological mechanisms were better understood, they may inform the current 
inconsistency among studies and trials addressing selenium and risk of cancer, especially prostate 
cancer. Hence, in the current cross-sectional study we investigated the association between serum 
selenium and serum concentrations of sex steroid hormones including estradiol in a nationally 
representative sample of US men to inform one mechanism by which selenium may influence 
prostate cancer risk.  
 
Methods 
Study population 
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NHANES III was conducted by the National Center for Health Statistics (NCHS) between 1988 and 
1994 (13) and designed as a multistage stratified, clustered probability sample of the US civilian non-
institutionalized population who was at least two months old. All participants were interviewed at 
home and underwent an extensive physical examination, including a blood sample performed at a 
mobile examination center (13). NHANES III was conducted in two phases (1988-1991 and 1991-
1994) which both lead to independent unbiased national estimates of health and nutrition 
characteristics. Within each phase, participants were randomly assigned to enter either the morning 
or afternoon/evening examination session. Of the 2,205 men, who took part in the morning session 
of Phase I (1988-1991), we selected all men aged 20+ years with no history of prostate cancer, who 
had serum total testosterone, total estradiol, SHBG, androstanediol glucuronide (AAG), as well 
serum selenium measured (n=1,420). 
 
Hormone measurements 
Sex steroid hormones were assayed using stored serum samples at Children’s Hospital Boston, MA. 
Competitive electrochemiluminescence immunoassays on the 2010 Elecsys autoanalyzer (Roche 
Diagnostics, Indianapolis, IN) were used to measure testosterone, estradiol, and SHBG 
concentrations in 2005. AAG, an indicator of the conversion of testosterone to dihydrotestosterone, 
was assessed with an enzyme immunoassay (Diagnostic Systems Laboratories, Webster, TX). 
Laboratory technicians were blinded to participant characteristics. These assays had the following 
detection limits for testosterone, estradiol, AAG, and SHBG: 0.02 ng/mL, 5 pg/mL, 0.33 ng/mL, and 3 
nmol/L, respectively. The coefficients of variation for quality control specimens were measured for 
two or three concentrations each: 5.9% and 5.8% at 2.5 and 5.5 ng/ml for testosterone; 2.5%, 6.5%, 
and 6.7% at 39.4, 102.7 and 474.1 pg/mL for estradiol; 9.5% and 5.0% at 2.9 and 10.1 ng/mL for 
AAG; and 5.3% and 5.9% at 5.3 and 16.6 nmol/L for SHBG. The interassay coefficient of variation for 
quality control samples with a mean estradiol concentration of 39.4 pg/nL (within the typical range 
for adults males) was 2.5% (14). Predefined formulas were used to estimate free testosterone and 
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estradiol using each man’s total testosterone and SHBG concentrations, along with the population 
normal albumin concentration in men (15, 16).  
 
Exposure measurements and covariates 
Serum selenium concentrations were measured in venous blood samples taken during the NHANES 
examinations using atomic absorption spectrometry (17). Information on age, race/ethnicity, 
income, cigarette smoking, and physical activity was collected by interview. The following activities 
were used to define vigorous physical activity: jogging or running; swimming or aerobics (for men 40 
years or older); biking, dancing, gardening, and calisthenics (for men 65 years or older); and walking 
and lifting weights (for men 80 years and older). Frequency of alcohol consumption was measured 
by a food frequency questionnaire and categorized by times per week. Percent body fat was 
estimated from anthropometric and bioelectrical impedance data using the equations of Chumlea 
and colleagues (18). Serum cotinine levels were measured as previously described (19). 
 
The protocols for the conduct of NHANES III were approved by the Institutional Review Board of the 
NCHS, Centers for Disease Control and Prevention. All participants provided written informed 
consent. The assay of stored serum specimens for the Hormone Demonstration Program was 
approved by the Institutional Review Boards at the Johns Hopkins Bloomberg School of Public Health 
and the NCHS, Centers for Disease Control and Prevention. 
 
Statistical Analysis 
We used phase I morning sampling weights for NHANES III to account for sampling variability and 
adjust for differential probability of selection of persons (13). Age-adjusted means or percentages of 
characteristics of the men by quartiles of serum selenium concentration were calculated after 
adjusting for the age distribution of the US population according to the 2000 Census. Next, we 
calculated adjusted geometric mean concentrations of the sex steroid hormones and their 95% 
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confidence intervals (CI) by quartiles of serum selenium using linear regression. As the hormone 
concentrations were not normally distributed, we used log-transformations. Multivariable models 
was adjusted for age (continuous), race/ethnicity, and factors that have been associated with 
hormone concentrations in previous NHANES III analyses: cigarette smoking (never, former, 
current), serum cotinine (continuous), household income (<$20,000 and ≥$20,000), vigorous 
physical activity (yes or no), alcohol intake (0, <2, 2-3, 4-6 times a week, or daily or more), and 
percent body fat (continuous).  
 
For those sex steroid hormones for which the multivariable models indicated a trend across 
selenium quartiles, we conducted further stratified analyses. Specifically, we assessed whether age 
(20-40, 40-60, and 60+ years), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican-
American, other), smoking status (never, former, current), or alcohol consumption (never, <2, 2+ 
drinks per week) modified the association between serum selenium and sex steroid hormones. 
Given the strong potential for confounding by smoking and alcohol drinking, we investigated the 
association between sex steroid hormones and selenium within never smokers and those with 
limited alcohol consumption (<2 drinks per week). Interaction was assessed by adding an interaction 
term and testing its coefficient using the Wald test.  
 
All statistical analyses were conducted with SAS release 9.2 (SAS Institute, Cary, NC) and SUDAAN 9.0 
software (Research Triangle Park, NC) as implemented in SAS 9.2. 
 
Results 
In this sample of men 20+ years old in NHANES III, those with selenium levels ≥122 ng/mL (i.e., third 
and fourth quartile) were more likely to be non-Hispanic white, to be never smokers, and to 
participate in vigorous physical activity (only those with selenium levels ≥133 ng/mL), as compared 
to those with selenium levels <122 ng/mL (Table 1). More specifically, those with selenium levels 
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<122 ng/mL were more likely to be non-Hispanic black, to be smokers, to have lower household 
income, to have a higher percent body fat, but drink fewer alcoholic drinks (Table 1). 
 
Adjusting for age and race/ethnicity, mean total and free estradiol concentrations were statistically 
significantly lower in men with higher selenium concentrations (Table 2). These differences in total 
and free estradiol levels were attenuated, but remained statistically significant after further 
adjustment for smoking status, cotinine levels, alcohol consumption, physical activity, income, and 
percent body fat. This inverse association was also observed for the estradiol/total testosterone 
ratio, but no associations were observed for total or free testosterone, AAG, and SHBG and serum 
selenium in these multivariate models (Table 2). 
 
Estradiol decreased across quartiles of serum selenium in both non-Hispanic black and white (Table 
3). However, this trend was not statistically significant, and also less obvious for Mexican-American 
men and men of other race/ethnicities. The inverse association between estradiol and selenium was 
only apparent among never smokers (Pinteraction=0.073), and those who drank <2 alcoholic drinks per 
week (Pinteraction= 0.017). Additionally, the inverse association between estradiol and selenium was 
most notable in those age 60+ years (Pinteraction=0.618).  
 
Discussion 
In this nationally representative sample of US men, we observed that mean total estradiol and free 
estradiol concentrations decreased over quartiles of selenium. Stratification by smoking and alcohol 
consumption showed that the latter observation was stronger for never smokers and those with 
limited alcohol intake.  
 
Selenium is required for normal thyroid function, but its link with the balance of sex steroid 
hormone levels remains to be defined (12, 20). While the studies by Zengt et al (20) and Rotter et al 
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(12) did not find any associations, a study investigating the association between serum levels of 
testosterone and selenium in infertile men attending a fertility clinic in South-East Nigeria, found a 
strong positive association (21). However, in the context of development of cancer, our finding of an 
inverse association between selenium and estradiol is in line with previous animal studies for breast 
cancer (22). Lee et al. investigated the effect of selenium on estrogen receptor (ER) expression and 
activation using methylselenic acid (MSA), an active form of selenium in human breast cancer cells 
(22). Selenium was found to decrease expression of ERalpha mRNA and protein and increased 
ERbeta mRNA expression in this in vitro study. This differential regulation of ERalpha and ERbeta in 
breast cancer cells has been proposed as a novel mechanism of selenium action in the context of 
breast cancer prevention (22). In the context of prostate cancer, the mechanism of action remains to 
be determined. Only one study has investigated the association between selenium and estradiol in 
the context of prostate cancer, but no association was found (23). However, several experimental 
studies support the observation that estrogens might play a role in prostatic carcinogenesis (24, 25).  
Even though we observed an inverse association between selenium and estradiol across 
racial/ethnic groups in NHANES, the higher estradiol concentration in non-Hispanic black men 
compared to non-Hispanic white men supports the known higher risk of prostate cancer in black 
men (14).  The findings for the stratifications by smoking behavior, alcohol consumption and age 
require further biological studies as it is unclear why the associations were stronger in the non-
smokers, those with limited alcohol consumption, and those of older age.   
 
This is one of the largest studies assessing the concentrations of sex steroid hormones in relation to 
selenium. The sampling design of NHANES makes our findings applicable to the US population of 
civilian non-institutionalized men aged 20 years and older.  We were also able to adjust for a wide 
range of potential confounding factors including lifestyle factors and race/ethnicity. As our study is a 
cross-sectional evaluation of the link between sex steroid hormones and selenium and it was not 
possible to assess temporality. Studies on sex steroid hormones are limited by high level of the 
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intersubject and intrasubject variability in the production, circulating levels, and metabolic clearance 
rates of steroid hormones resulting from changes in the diurnal rhythm. Here, we aimed to minimize 
the influence of variation resulting from diurnal production of the hormones by selecting 
participants with morning samples. Another limitation of this study is the lack of information on 
selenium concentrations in toenails, as the association with prostate cancer risk has been shown to 
vary based on selenium measurements (2). The data collection prior to implementation of PSA 
testing may also have resulted in the lack of prostate cancer diagnosis for some men – though these 
are though to be indolent cancers (26). 
 
Conclusion 
This cross-sectional study suggests that a possible mechanism by which selenium may be protective 
for prostate cancer is related to estrogen. Further studies of longitudinal measurements of serum 
and toenail selenium in relation to serum measurements of sex steroid hormones are needed. These 
studies would also benefit from having more detailed data on PSA measurements as well prostate 
biopsy tissue.  
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